Table 3 Univariate analysis of preoperative factors associated with unresectability
Unresectable (n = 4) | Successful (n = 27) | P value | |
|---|---|---|---|
Results | % (n) | % (n) | |
Clinical presentation | |||
Bloatedness | 75% (3/4) | 15% (4/26) | 0.03* |
Altered bowel habits | 50% (2/4) | 12% (3/26) | 0.12 |
Abdominal pain | 50% (2/4) | 15% (4/26) | 0.17 |
Loss of weight | 50% (2/4) | 8% (2/26) | 0.08 |
Nausea/vomiting | 25% (1/4) | 8% (2/26) | 0.36 |
Abdominal distension | 0.0% (0/4) | 4% (1/26) | 1.00 |
Abdominal mass | 25% (1/4) | 0.0% (0/26) | 0.04* |
Pouch of Douglas nodules | 0.0% (0/4) | 0.0% (0/26) | – |
Disease factor | |||
High-grade tumour | 50% (2/4) | 4% (0/27) | 0.01* |
Prior neoadjuvant chemotherapy | 75% (3/4) | 96% (26/27) | 0.25 |
Neoadjuvant cycles (median months) | 9 (3 to 15) | 6 (2 to 12) | 0.14 |
Multiple lines of chemotherapy | 50% (1/2) | 29% (7/24) | 0.04* |
Response to chemotherapy | |||
Complete response | 0.0% (0/3) | 76% (16/21) | |
Partial response | 67% (2/3) | 10% (2/21) | 0.11 |
No response | 0.0% (0/3) | 14% (3/21) | 0.20 |
Progressive disease | 33% (1/3) | 0.0% (0/21) | 0.00* |
Suboptimal resection | 25% (1/4) | 7% (2/27) | 0.04* |
Disease-free interval (median months) | 14 (4 to 16) | 16 (0 to 62) | 0.23 |
Preoperative investigations | |||
Elevated tumour markers | 100% (4/4) | 50% (11/22) | 0.03* |
Thrombocytosis | 50% (2/4) | 15% (4/27) | 0.16 |
Anaemia | 25% (1/4) | 41% (11/27) | 1.00 |
Hypoalbuminemia | 50% (2/4) | 33% (9/27) | 0.60 |
CT ascites | 100% (4/4) | 9% (2/23) | 0.00* |
CT omental thickening | 100% (4/4) | 4% (1/23) | 0.00* |
CT lymphadenopathy | 25% (1/4) | 17% (4/23) | 1.00 |
CT small bowel disease | 25% (1/4) | 8% (2/23) | 0.01* |